Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Is a Beat in Store for Gilead (GILD) in This Earnings Season?
02:10pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) second-quarter 2022 results.
CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?
04:19pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.
Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?
02:51pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.
Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?
12:25pm, Wednesday, 27'th Jul 2022
Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.
Pfizer (PFE) to Report Q2 Earnings: What's in the Cards?
03:28pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the second quarter.
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
02:24pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to c
AstraZeneca: Q2 2022 Earnings May Not Wow Investors - Steady Growth's The Charm
03:16pm, Monday, 25'th Jul 2022
AstraZeneca will announce Q222 earnings this Friday, July 29. The company has driven >90% share price growth over the past five years.
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
03:06pm, Monday, 25'th Jul 2022 Zacks Investment Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.
GSK Gears Up to Report Q2 Earnings: What's in the Cards?
02:59pm, Monday, 25'th Jul 2022 Zacks Investment Research
The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company report
U.S. Stock Futures Higher; Crude Oil Rises 1%
10:35am, Monday, 25'th Jul 2022 Benzinga
Pre-open movers
U.S. stock futures traded higher in early pre-market trade on Monday after the Nasdaq Composite jumped around 1.4% the previous session. Investors are awaiting earnings results from R
AstraZeneca delivers a triple dose of drug updates
03:13am, Monday, 25'th Jul 2022
AstraZeneca PLC (LSE:AZN) on Monday revealed why it is considered to have one of the strongest drug pipelines in the life sciences industry with three major announcements in the space of five minutes.
2 Unstoppable Stocks Set to Keep Beating the Market in 2022
12:00pm, Saturday, 23'rd Jul 2022 The Motley Fool
Their drug prospects are helping them perform better than most stocks on the market this year.
2 Unstoppable Stocks Set to Keep Beating the Market in 2022
08:00am, Saturday, 23'rd Jul 2022
Their drug prospects are helping them perform better than most stocks on the market this year.
Astrazeneca (AZN) Stock Moves -0.17%: What You Should Know
10:15pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Astrazeneca (AZN) closed the most recent trading day at $65.25, moving -0.17% from the previous trading session.
2 Pharma Giants With Momentum That Could Carry Through 2030
03:30pm, Friday, 22'nd Jul 2022 The Motley Fool
An obese population could drive competition toward a valuable market.
